Our Products
Loans
Cards
Insurance
Investment
Stock Market
Electronics Mall
CIBIL Score
Knowledge Centre
Academy 
Calculators
Our Services
My Account
Do not call
En
Coral Laboratories Ltd. Share Price
Day's Range
Low
₹
High
₹
Financials
| Particulars | QTR FY (₹ in Millions) | Annual FY (₹ in Millions) |
|---|---|---|
| Net sales | 188.21 | 1150.05 |
| Expenses | N/A | N/A |
| PBT | 37.2 | 324.7 |
| Operating profit | 0.0 | 0.0 |
| Net profit | 25.64 | 241.56 |
About Coral Laboratories Ltd.
| Founded | 1997 |
|---|
Peer Comparision
| Stocks Name | Market Cap (Cr)(₹) | Market Price (₹) | 52 Week Low-High (₹) |
|---|---|---|---|
| Sun Pharmaceutical Industries Ltd. | 4,24,202.42 | 1,768.00 | 1,583.70 - 1,583.70 |
| Divi's Laboratories Ltd. | 2,64,141.24 | 9,950.00 | 5,647.50 - 5,647.50 |
| Torrent Pharmaceuticals Ltd. | 1,74,402.47 | 4,585.10 | 3,532.60 - 3,532.60 |
| Laurus Labs Ltd. | 1,26,811.28 | 2,347.00 | 917.95 - 917.95 |
| Zydus Lifesciences Ltd. | 1,23,685.49 | 1,239.95 | 835.50 - 835.50 |
| Apollo Hospitals Enterprise Ltd. | 1,21,066.68 | 8,420.00 | 6,696.50 - 6,696.50 |
| Lenskart Solutions Ltd. | 1,15,707.34 | 671.20 | 0.00 - 0.00 |
| Dr. Reddy's Laboratories Ltd. | 1,11,868.03 | 1,340.25 | 1,101.00 - 1,101.00 |
| Cipla Ltd. | 1,11,650.13 | 1,382.00 | 1,165.70 - 1,165.70 |
| Mankind Pharma Ltd. | 1,02,195.62 | 2,475.95 | 1,909.70 - 1,909.70 |
No Records Found
Latest News
Coral Laboratories submits board meeting intimation
AstraZeneca Pharma India informs about updates
GPT Healthcare informs about earnings call
In compliance with Regulation 30 read with Part A of Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, GPT Healthcare has informed an Earnings Call is scheduled on Friday, November 6, 2026 at 11.00 A.M (IST) to discuss the financial performance of the Company on the Un-Audited Financial Results for the for the 2nd quarter and half year ended September 30, 2026. In this regard, the company has enclosed conference call details with this letter.
The above information is a part of company’s filings submitted to BSE.
Divi's Laboratories informs about earnings call
Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, Divi's Laboratories has informed that it enclosed the schedule of earnings conference call for the quarter and half year ended September 30, 2026, to be held on November 07, 2026.
The above information is a part of company’s filings submitted to BSE.
IOL Chemicals and Pharmaceuticals submits investor presentation
No Records Found
Sign in to Unlock Offers!
We don't SPAM
Frequently Asked Questions
The current share price of Coral Laboratories Ltd. is ₹499.70 as of 2026-11-02.
The market capitalisation of Coral Laboratories Ltd. is ₹178.52 as of 2026-11-02.
The 1-year return of Coral Laboratories Ltd. is -9.70% as of 2025-10-31.
The P/E ratio of Coral Laboratories Ltd. is 10.37 as of 2026-11-02.
The 52-week high and low of Coral Laboratories Ltd. are ₹679.00 and ₹360.00, respectively, as of 2026-11-02.
Disclaimer
All content and research information displayed on the Site, are obtained from our partner Accord Fintech Private Limited. an authorized data feed vendor of BSE/NSE/MCX/NCDEX exchange. The data is provided on ‘As-Is’ basis and is not a live data feed but a feed with 15 minutes delay or more. Bajaj Markets does not warrant accuracy, completeness, timely availability of the information and data available on the Site. Past performance, when presented, is purely for reference purposes and is not a guarantee of similar future results.
The Services offered on the Site does not constitute investment advice in any manner whatsoever. You shall be solely responsible for any investment decisions made by placing reliance on the information provided on the Site.
Bajaj Markets partners with financial services entities for sourcing leads for services such as DEMAT accounts etc. In case you wish to avail the services, you shall be redirected to partners platform and shall be bound by the terms and conditions, privacy policy governing the said platform.
